
About Dishman Carbogen Amcis
Dishman Carbogen Amcis is a publicly listed company based in Ahmedabad (India) founded in 1983 by Janmejay R Vyas. Active pharmaceutical ingredients are manufactured by the CDMO in India. The company has 1,122 employees. Its website imdcal.com draws about 17 thousand monthly visits. Its Indian entity Dishman Carbogen Amcis Limited reported revenue of βΉ2,988 Cr. Dishman Carbogen Amcis offers products and services including CRAMS Services, API Manufacturing, Analytical Capabilities, Finished Dosages, and Quaternary Salts. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.
Company details
Dishman Carbogen Amcis was established in 1983 in Ahmedabad, India, by founder Janmejay R Vyas. Operations are centered on contract development and manufacturing services for active pharmaceutical ingredients within the pharmaceutical sector. Production facilities are maintained in India, supporting API synthesis and related processes for international clients. The focus remains on reliable manufacturing capabilities without additional diversification noted.
- Headquarters Ahmedabad, India
- Employees 1,122
- Founders Janmejay R Vyas
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website imdcal.com
- Social LinkedIn
- Legal Name Dishman Carbogen Amcis Ltd.
- Market Cap₹1,858 Cr
DCAL · NSE
- Share Price₹115.90
-2.22% today
- Revenue₹2,932 Cr
FY 2025-26 · +8.1% YoY
- EBITDA₹562 Cr
Margin 19.2%
- Net Profit₹98.68 Cr
FY 2025-26 · +639.8% YoY
- ROE1.6%
ROCE 2.8%
- Debt / Equity0.44
Interest cover 78.1x
- Employee Count1,122
Associated legal entities of Dishman Carbogen Amcis
Dishman Carbogen Amcis operates through Dishman Carbogen Amcis Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Limited Listed CIN L74900GJ2007PLC051338 | Active | 17 Jul 2007 | Ahmedabad, Gujarat | ₹2,988 Cr | 791 | 8 | View details |
Products & Services of Dishman Carbogen Amcis
Dishman Carbogen Amcis offers a comprehensive portfolio of products and services, including CRAMS Services, API Manufacturing, Analytical Capabilities, Finished Dosages, and Quaternary Salts.
Offers contract research for pharmaceutical API development.
Provides highly potent API supply and production.
Delivers quality analysis for pharmaceutical products.
Includes health and personal care formulations.
Specializes in encapsulation and formulation capabilities.
Board of directors of Dishman Carbogen Amcis Limited (Dishman Carbogen Amcis)
Dishman Carbogen Amcis Limited is the primary company behind Dishman Carbogen Amcis. The board of Dishman Carbogen Amcis Limited currently have 7 directors; the longest-serving is Arpit Janmejay Vyas, appointed in 2012. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Arpit Janmejay Vyas DIN 01540057 | Managing Director | 07 Apr 2012 | 14 yrs 7 mo | Dishman Carbogen Amcis Limited |
| Deohooti Janmejay Vyas DIN 00004876 | Whole-time director | 17 Mar 2017 | 9 yrs 8 mo | Dishman Carbogen Amcis Limited |
| Harshil Ramakant Dalal DIN 06481203 | CFO | 28 Nov 2018 | 7 yrs 11 mo | Dishman Carbogen Amcis Limited |
| Kulin Nalinkant Shah DIN 01863481 | Director | 13 Nov 2024 | 2 yrs | Dishman Carbogen Amcis Limited |
| Hemantkumar Jayantiprasad Bhatt DIN 02657432 | Director | 01 Apr 2025 | 1 yr 7 mo | Dishman Carbogen Amcis Limited |
| Margie Parikh DIN 07056179 | Director | 01 Apr 2025 | 1 yr 7 mo | Dishman Carbogen Amcis Limited |
| Dhaval Rameshchandra Shah DIN 09385325 | Director | 12 Aug 2025 | 1 yr 3 mo | Dishman Carbogen Amcis Limited |
People of Dishman Carbogen Amcis
10 people are tracked at Dishman Carbogen Amcis (10 in leadership); the tracked headcount is 1,122.
| Name | Role | Group |
|---|---|---|
| Founder | Leadership | |
Pascal Villemagne | Chief Executive Officer (carbogen Amcis) | Leadership |
| Global Managing Director | Leadership | |
Paolo Armanino | Chief Operating Officer India | Leadership |
Stephan Fritschi | Executive Vice-president Business Units; Deputy CEO (carbogen Amcis) | Leadership |
Alan Fischer | Vice President Innovation & M&a (carbogen Amcis) | Leadership |
François Baduel | Vice President Sales & Marketing (carbogen Amcis) | Leadership |
Martin Schneider | Vice President Quality & ESH (carbogen Amcis) | Leadership |
| Global Chief Financial Officer | Leadership | |
Dieter Thüer | Vice President Human Resources (carbogen Amcis) | Leadership |
Complete people profiles for Dishman Carbogen Amcis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Dishman Carbogen Amcis
Dishman Carbogen Amcis is a publicly listed company on the NSE with ticker symbol DCAL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Sep 2017
- Listed onNSE: DCAL · BSE: 540701
- Listed entityDishman Carbogen Amcis Ltd.
- Exchange sectorHealth technology
- ISININE385W01011
- Share price₹153.04 (+1.65% on the day) · 2026-10-14
- Market capitalisation₹2,365 Cr
- Price to earnings35.2
- EPS (diluted, trailing year)₹4.35
- Volume (last session)143,223
Financials of Dishman Carbogen Amcis
Exchange-reported figures of Dishman Carbogen Amcis Limited, the listed company behind Dishman Carbogen Amcis (NSE: DCAL).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2,932 | 2,712 | 2,616 | 2,413 | 2,141 | 1,912 | 2,044 |
| Revenue growth | +8.1% | +3.7% | +8.4% | +12.7% | +12.0% | -6.4% | - |
| EBITDA | 562 | 451 | 280 | 284 | 317 | 252 | 498 |
| EBITDA margin | +19.2% | +16.6% | +10.7% | +11.8% | +14.8% | +13.2% | +24.4% |
| Profit before tax | 105 | 19.31 | (122) | (54.59) | (4.25) | (65.03) | 197 |
| Net profit | 98.68 | (18.28) | (151) | (8.36) | 49.61 | (170) | 163 |
| Net profit margin | +3.4% | -0.7% | -5.8% | -0.4% | +2.3% | -8.9% | +8.0% |
| EPS (βΉ) | 6.21 | 0.21 | (9.79) | (1.90) | 1.15 | (10.53) | 10.10 |
| Balance sheet | |||||||
| Total assets | 10,912 | 9,062 | 8,768 | 8,419 | 7,809 | 7,604 | 7,367 |
| Net worth | 6,677 | 5,832 | 5,628 | 5,810 | 5,549 | 5,699 | 5,715 |
| Total debt | 3,076 | 2,389 | 2,313 | 2,209 | 1,830 | 1,589 | 1,357 |
| Cash & bank | 991 | 507 | 413 | 189 | 172 | 308 | 161 |
| Net working capital | 1,827 | 1,250 | 1,131 | 782 | 846 | 1,017 | 984 |
| Cash flow | |||||||
| Cash from operations | 491 | 371 | 379 | 266 | 355 | 513 | 585 |
| Cash from investing | (245) | (192) | (225) | (494) | (619) | (380) | (442) |
| Cash from financing | 201 | (102) | (22.15) | 250 | 130 | (11.04) | (97.78) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 507 | 678 | 851 | 720 | 653 | 708 | 716 | 682 |
| Revenue growth (YoY) | -22.3% | -4.3% | +18.9% | +5.5% | -17.3% | +35.2% | - | - |
| Other income | 3.56 | 18.16 | 16.42 | 6.66 | 8.11 | 24.75 | 7.97 | 7.67 |
| EBITDA | 45.96 | 58.39 | 162 | 113 | 149 | 138 | 141 | 140 |
| EBITDA margin | +9.1% | +8.6% | +19.0% | +15.7% | +22.8% | +19.5% | +19.7% | +20.5% |
| Depreciation | 90.42 | 90.68 | 88.79 | 84.42 | 84.13 | 81.35 | 79.09 | 71.97 |
| Interest | 40.10 | 37.09 | 43.30 | 45.79 | 42.33 | 42.76 | 42.12 | 48.78 |
| Profit before tax | (81.00) | (51.22) | 46.13 | (10.44) | 30.54 | 38.67 | 27.70 | 27.05 |
| Tax | (14.27) | 6.66 | 24.39 | 2.53 | (34.73) | 15.26 | (15.39) | 22.42 |
| Net profit | (66.73) | (57.88) | 21.74 | (12.97) | 65.27 | 23.41 | 43.09 | 4.63 |
| EPS (βΉ) | (4.26) | (3.69) | 1.39 | (0.83) | 4.16 | 1.49 | 2.75 | 0.30 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 232 | 400 | 327 | 403 | 307 | 200 | 581 |
| Revenue growth | -42.1% | +22.1% | -18.7% | +31.3% | +53.1% | -65.5% | - |
| EBITDA | 5.32 | 71.79 | 3.75 | 5.76 | 32.52 | (59.32) | 174 |
| EBITDA margin | +2.3% | +18.0% | +1.2% | +1.4% | +10.6% | -29.6% | +29.9% |
| Profit before tax | (59.25) | (30.83) | (103) | (96.20) | (84.39) | (169) | 55.46 |
| Net profit | (39.53) | (11.18) | (75.39) | (56.08) | (30.76) | (235) | 42.58 |
| Net profit margin | -17.1% | -2.8% | -23.0% | -13.9% | -10.0% | -117.5% | +7.3% |
| EPS (βΉ) | (2.45) | (0.63) | (4.87) | (3.75) | (2.01) | (14.85) | 2.46 |
| Balance sheet | |||||||
| Total assets | 4,767 | 4,892 | 4,787 | 4,910 | 4,946 | 5,220 | 5,396 |
| Net worth | 3,882 | 4,030 | 4,053 | 4,114 | 4,232 | 4,675 | 4,796 |
| Total debt | 634 | 686 | 536 | 593 | 535 | 538 | 573 |
| Cash & bank | 38.02 | 87.41 | 9.90 | 68.43 | 86.47 | 80.32 | 65.13 |
| Net working capital | 315 | 442 | 325 | 363 | 390 | 511 | 510 |
| Cash flow | |||||||
| Cash from operations | 46.11 | 55.81 | 24.17 | (52.90) | 227 | (1.51) | 197 |
| Cash from investing | 21.68 | (79.64) | 96.57 | 40.71 | (173) | 62.07 | (74.30) |
| Cash from financing | (120) | 87.51 | (131) | 1.38 | (46.16) | (70.53) | (124) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 83.59 | 57.08 | 68.72 | 39.68 | 60.30 | 62.86 | 106 | 97.04 |
| Revenue growth (YoY) | +38.6% | -9.2% | -35.2% | -59.1% | -35.4% | -39.2% | - | - |
| Other income | 3.79 | 18.89 | 28.83 | 7.10 | 11.17 | 37.42 | 5.47 | (8.01) |
| Total expenses | 83.10 | 70.59 | 67.74 | 43.18 | 55.89 | 59.43 | 85.57 | 74.08 |
| EBITDA | 0.49 | (13.51) | 0.98 | (3.50) | 4.41 | 3.43 | 20.53 | 22.96 |
| EBITDA margin | +0.6% | -23.7% | +1.4% | -8.8% | +7.3% | +5.5% | +19.3% | +23.7% |
| Depreciation | 15.00 | 15.37 | 15.15 | 15.16 | 15.79 | 16.47 | 16.10 | 16.48 |
| Interest | 23.04 | 21.71 | 22.14 | 23.51 | 20.61 | 20.26 | 21.31 | 17.77 |
| Profit before tax | (33.76) | (31.70) | (7.48) | (35.07) | (20.82) | 4.12 | (11.41) | (19.30) |
| Tax | (8.49) | (7.79) | (3.14) | (11.94) | (7.22) | 1.45 | (4.04) | (6.02) |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 507 | 678 | 851 | 720 | 653 | 708 | 716 | 682 |
| Revenue growth (YoY) | -22.3% | -4.3% | +18.9% | +5.5% | -17.3% | +35.2% | - | - |
| Other income | 3.56 | 18.16 | 16.42 | 6.66 | 8.11 | 24.75 | 7.97 | 7.67 |
| EBITDA | 45.96 | 58.39 | 162 | 113 | 149 | 138 | 141 | 140 |
| EBITDA margin | +9.1% | +8.6% | +19.0% | +15.7% | +22.8% | +19.5% | +19.7% | +20.5% |
| Depreciation | 90.42 | 90.68 | 88.79 | 84.42 | 84.13 | 81.35 | 79.09 | 71.97 |
| Interest | 40.10 | 37.09 | 43.30 | 45.79 | 42.33 | 42.76 | 42.12 | 48.78 |
| Profit before tax | (81.00) | (51.22) | 46.13 | (10.44) | 30.54 | 38.67 | 27.70 | 27.05 |
| Tax | (14.27) | 6.66 | 24.39 | 2.53 | (34.73) | 15.26 | (15.39) | 22.42 |
| Net profit | (66.73) | (57.88) | 21.74 | (12.97) | 65.27 | 23.41 | 43.09 | 4.63 |
| EPS (βΉ) | (4.26) | (3.69) | 1.39 | (0.83) | 4.16 | 1.49 | 2.75 | 0.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,932 | 2,712 | 2,616 | 2,413 | 2,141 | 1,912 | 2,044 |
| Revenue growth | +8.1% | +3.7% | +8.4% | +12.7% | +12.0% | -6.4% | - |
| Other income | 55.94 | 21.68 | 28.21 | 27.77 | 43.42 | 38.45 | 44.46 |
| Total expenses | 2,370 | 2,261 | 2,335 | 2,129 | 1,824 | 1,660 | 1,546 |
| Employee cost | 1,447 | 1,294 | 1,208 | 1,030 | 981 | 873 | 762 |
| EBITDA | 562 | 451 | 280 | 284 | 317 | 252 | 498 |
| EBITDA margin | +19.2% | +16.6% | +10.7% | +11.8% | +14.8% | +13.2% | +24.4% |
| Depreciation | 339 | 294 | 311 | 281 | 308 | 308 | 283 |
| Interest | 174 | 159 | 120 | 85.69 | 56.81 | 47.61 | 61.95 |
| Profit before tax | 105 | 19.31 | (122) | (54.59) | (4.25) | (65.03) | 197 |
| Tax | 7.45 | 16.07 | 31.19 | (24.79) | (22.26) | 100 | 38.69 |
| Net profit | 98.68 | (18.28) | (151) | (8.36) | 49.61 | (170) | 163 |
| Net profit margin | +3.4% | -0.7% | -5.8% | -0.4% | +2.3% | -8.9% | +8.0% |
| EPS (βΉ) | 6.21 | 0.21 | (9.79) | (1.90) | 1.15 | (10.53) | 10.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 31.36 | 31.36 | 31.36 | 31.36 | 31.36 | 31.36 | 31.38 |
| Reserves & surplus | 6,646 | 5,800 | 5,596 | 5,778 | 5,518 | 5,667 | 5,684 |
| Shareholders' funds (net worth) | 6,677 | 5,832 | 5,628 | 5,810 | 5,549 | 5,699 | 5,715 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 2,730 | 2,072 | 1,946 | 1,825 | 1,421 | 1,166 | 916 |
| Unsecured loans | 346 | 317 | 366 | 384 | 409 | 423 | 442 |
| Total debt | 3,076 | 2,389 | 2,313 | 2,209 | 1,830 | 1,589 | 1,357 |
| Total liabilities | 10,912 | 9,062 | 8,768 | 8,419 | 7,809 | 7,604 | 7,367 |
| Assets | |||||||
| Gross block | 12,419 | 10,551 | 10,314 | 9,463 | 8,639 | 8,161 | 7,896 |
| Net block | 8,076 | 7,055 | 6,724 | 6,188 | 5,773 | 5,698 | 5,678 |
| Capital work in progress | 570 | 467 | 646 | 1,043 | 780 | 486 | 234 |
| Investments | 91.45 | 97.39 | 102 | 249 | 324 | 172 | 191 |
| Inventories | 1,019 | 900 | 883 | 804 | 645 | 516 | 581 |
| Sundry debtors | 673 | 665 | 484 | 590 | 473 | 421 | 577 |
| Cash & bank balances | 991 | 507 | 413 | 189 | 172 | 308 | 161 |
| Loans & advances | 143 | 103 | 124 | 159 | 256 | 344 | 353 |
| Total current assets | 2,826 | 2,175 | 1,905 | 1,741 | 1,546 | 1,588 | 1,672 |
| Total current liabilities | 999 | 925 | 774 | 960 | 700 | 571 | 689 |
| Net working capital | 1,827 | 1,250 | 1,131 | 782 | 846 | 1,017 | 984 |
| Total assets | 10,912 | 9,062 | 8,768 | 8,419 | 7,809 | 7,604 | 7,367 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 341 | 264 | 132 | 110 | 244 | 122 | 76.32 |
| Net cash from operating activities | 491 | 371 | 379 | 266 | 355 | 513 | 585 |
| Net cash from investing activities | (245) | (192) | (225) | (494) | (619) | (380) | (442) |
| Net cash from financing activities | 201 | (102) | (22.15) | 250 | 130 | (11.04) | (97.78) |
| Net change in cash | 447 | 76.98 | 132 | 21.55 | (133) | 122 | 45.62 |
| Closing cash | 991 | 507 | 413 | 189 | 172 | 308 | 161 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +8.1% | +3.7% | +8.4% | +12.7% | +12.0% | -6.4% | - |
| EBITDA growth | +24.6% | +60.8% | -1.3% | -10.3% | +25.7% | -49.3% | - |
| PBT growth | +443.2% | +9998.0% | -124.0% | -1184.5% | +93.5% | - | -36.1% |
| Net income growth | +639.8% | +87.9% | -1707.3% | -116.9% | +129.1% | -204.4% | - |
| Revenue CAGR (3Y) | +6.7% | +8.2% | +11.0% | +5.7% | +1.3% | +4.1% | +6.0% |
| EBITDA CAGR (3Y) | +25.5% | +12.5% | +3.6% | -17.0% | -16.9% | -17.3% | +3.2% |
| Profitability & leverage | |||||||
| Net income margin | +3.3% | +0.1% | -5.9% | -1.2% | +0.8% | -8.6% | +7.8% |
| Return on capital employed | +2.8% | +2.2% | -0.0% | +1.0% | +0.8% | +0.0% | +3.7% |
| Return on net worth | +1.6% | -0.3% | -2.7% | -0.2% | +0.9% | -3.0% | +2.9% |
| Debt / equity | 0.44 | 0.41 | 0.40 | 0.36 | 0.30 | 0.26 | 0.22 |
| Long-term debt / equity | 0.25 | 0.17 | 0.17 | 0.22 | 0.18 | 0.12 | 0.08 |
| Interest cover | 78.06 | 101.51 | -393.34 | 2,573.27 | 621.55 | -85.22 | 28.86 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.26 | 0.26 | 0.26 | 0.27 | 0.25 | 0.24 | 0.28 |
| Inventory turnover | 3.06 | 3.04 | 3.10 | 3.33 | 3.69 | 3.49 | 3.62 |
| Debtors turnover | 4.38 | 4.72 | 4.87 | 4.54 | 4.79 | 3.83 | 4.00 |
| EPS (βΉ) | 6.21 | 0.21 | (9.79) | (1.90) | 1.15 | (10.53) | 10.10 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 425.82 | 371.91 | 358.90 | 370.51 | 353.89 | 363.45 | 364.25 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 83.59 | 57.08 | 68.72 | 39.68 | 60.30 | 62.86 | 106 | 97.04 |
| Revenue growth (YoY) | +38.6% | -9.2% | -35.2% | -59.1% | -35.4% | -39.2% | - | - |
| Other income | 3.79 | 18.89 | 28.83 | 7.10 | 11.17 | 37.42 | 5.47 | (8.01) |
| Total expenses | 83.10 | 70.59 | 67.74 | 43.18 | 55.89 | 59.43 | 85.57 | 74.08 |
| EBITDA | 0.49 | (13.51) | 0.98 | (3.50) | 4.41 | 3.43 | 20.53 | 22.96 |
| EBITDA margin | +0.6% | -23.7% | +1.4% | -8.8% | +7.3% | +5.5% | +19.3% | +23.7% |
| Depreciation | 15.00 | 15.37 | 15.15 | 15.16 | 15.79 | 16.47 | 16.10 | 16.48 |
| Interest | 23.04 | 21.71 | 22.14 | 23.51 | 20.61 | 20.26 | 21.31 | 17.77 |
| Profit before tax | (33.76) | (31.70) | (7.48) | (35.07) | (20.82) | 4.12 | (11.41) | (19.30) |
| Tax | (8.49) | (7.79) | (3.14) | (11.94) | (7.22) | 1.45 | (4.04) | (6.02) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 232 | 400 | 327 | 403 | 307 | 200 | 581 |
| Revenue growth | -42.1% | +22.1% | -18.7% | +31.3% | +53.1% | -65.5% | - |
| Other income | 84.52 | 32.98 | 63.05 | 52.16 | 60.39 | 66.15 | 69.55 |
| Total expenses | 226 | 328 | 324 | 397 | 274 | 260 | 407 |
| Employee cost | 86.63 | 90.15 | 91.54 | 86.13 | 79.04 | 58.23 | 88.87 |
| EBITDA | 5.32 | 71.79 | 3.75 | 5.76 | 32.52 | (59.32) | 174 |
| EBITDA margin | +2.3% | +18.0% | +1.2% | +1.4% | +10.6% | -29.6% | +29.9% |
| Depreciation | 62.57 | 65.20 | 102 | 96.20 | 140 | 141 | 141 |
| Interest | 86.52 | 70.40 | 68.19 | 57.92 | 37.23 | 34.17 | 47.02 |
| Profit before tax | (59.25) | (30.83) | (103) | (96.20) | (84.39) | (169) | 55.46 |
| Tax | (20.85) | (20.96) | (26.59) | (37.33) | (52.84) | 64.12 | 16.94 |
| Net profit | (39.53) | (11.18) | (75.39) | (56.08) | (30.76) | (235) | 42.58 |
| Net profit margin | -17.1% | -2.8% | -23.0% | -13.9% | -10.0% | -117.5% | +7.3% |
| EPS (βΉ) | (2.45) | (0.63) | (4.87) | (3.75) | (2.01) | (14.85) | 2.46 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 31.36 | 31.36 | 31.36 | 31.36 | 31.36 | 31.36 | 31.38 |
| Reserves & surplus | 3,851 | 3,999 | 4,021 | 4,083 | 4,200 | 4,643 | 4,764 |
| Shareholders' funds (net worth) | 3,882 | 4,030 | 4,053 | 4,114 | 4,232 | 4,675 | 4,796 |
| Secured loans | 631 | 658 | 524 | 590 | 527 | 526 | 391 |
| Unsecured loans | 3.55 | 28.03 | 11.74 | 3.55 | 7.86 | 11.74 | 181 |
| Total debt | 634 | 686 | 536 | 593 | 535 | 538 | 573 |
| Total liabilities | - | - | 4,787 | 4,910 | 4,946 | 5,220 | 5,396 |
| Assets | |||||||
| Gross block | 2,655 | 2,622 | 2,573 | 2,457 | 2,339 | 2,364 | 2,344 |
| Net block | 1,372 | 1,401 | 1,416 | 1,382 | 1,356 | 1,510 | 1,633 |
| Capital work in progress | 22.97 | 40.70 | 74.05 | 143 | 118 | 121 | 88.85 |
| Investments | 2,844 | 2,841 | 2,848 | 2,913 | 3,032 | 2,882 | 2,900 |
| Inventories | 155 | 134 | 170 | 183 | 197 | 184 | 214 |
| Sundry debtors | 171 | 175 | 184 | 147 | 65.66 | 119 | 145 |
| Cash & bank balances | 38.02 | 87.41 | 9.90 | 68.43 | 86.47 | 80.32 | 65.13 |
| Loans & advances | 310 | 263 | 210 | 176 | 196 | 273 | 284 |
| Total current assets | 674 | 659 | 573 | 574 | 545 | 656 | 708 |
| Total current liabilities | 359 | 217 | 248 | 211 | 154 | 145 | 197 |
| Net working capital | 315 | 442 | 325 | 363 | 390 | 511 | 510 |
| Total assets | 4,767 | 4,892 | 4,787 | 4,910 | 4,946 | 5,220 | 5,396 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 67.73 | 4.05 | 14.07 | 24.88 | 16.36 | 26.33 | 28.00 |
| Net cash from operating activities | 46.11 | 55.81 | 24.17 | (52.90) | 227 | (1.51) | 197 |
| Net cash from investing activities | 21.68 | (79.64) | 96.57 | 40.71 | (173) | 62.07 | (74.30) |
| Net cash from financing activities | (120) | 87.51 | (131) | 1.38 | (46.16) | (70.53) | (124) |
| Net change in cash | (51.80) | 63.68 | (10.02) | (10.81) | 8.52 | (9.97) | (1.67) |
| Closing cash | 38.02 | 87.41 | 9.90 | 68.43 | 86.47 | 80.32 | 65.13 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -42.1% | +22.1% | -18.7% | +31.3% | +53.1% | -65.5% | - |
| EBITDA growth | -92.6% | +1814.4% | -34.9% | -82.3% | +154.8% | -134.2% | - |
| PBT growth | -92.2% | +70.1% | -7.1% | -14.0% | +50.0% | - | -32.1% |
| Net income growth | -253.6% | +85.2% | -34.4% | -82.3% | +86.9% | -652.7% | - |
| Revenue CAGR (3Y) | -16.8% | +9.3% | +17.8% | -11.5% | -17.7% | -25.0% | +8.8% |
| EBITDA CAGR (3Y) | -2.6% | +30.2% | - | -67.9% | -44.8% | - | +5.4% |
| Profitability & leverage | |||||||
| Net income margin | -16.6% | -2.5% | -23.3% | -14.6% | -10.3% | -116.2% | +6.6% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +2.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +0.9% |
| Debt / equity | 0.17 | 0.15 | 0.14 | 0.14 | 0.12 | 0.12 | 0.12 |
| Long-term debt / equity | 0.05 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.04 |
| Interest cover | -151.13 | 1,068.29 | -69.68 | -64.04 | -34.62 | -17.03 | 142.79 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.09 | 0.15 | 0.13 | 0.17 | 0.13 | 0.09 | 0.25 |
| Inventory turnover | 1.60 | 2.63 | 1.86 | 2.12 | 1.61 | 1.01 | 2.66 |
| Debtors turnover | 1.34 | 2.23 | 1.98 | 3.79 | 3.32 | 1.52 | 4.22 |
| EPS (βΉ) | (2.45) | (0.63) | (4.87) | (3.75) | (2.01) | (14.85) | 2.46 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 247.59 | 257.05 | 258.46 | 262.39 | 269.88 | 298.13 | 305.66 |
Similar companies to Dishman Carbogen Amcis
Dishman Carbogen Amcis has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed similar companies of Dishman Carbogen Amcis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dishman Carbogen Amcis
The website of Dishman Carbogen Amcis (imdcal.com) receives about 16.7K visits a month.
- Monthly visits16.7K
▼ 6.6% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Dishman Carbogen Amcis (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dishman Carbogen Amcis
Complete news archive for Dishman Carbogen Amcis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dishman Carbogen Amcis
Dishman Carbogen Amcis was founded in 1983.
Dishman Carbogen Amcis is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
Dishman Carbogen Amcis has 1,122 employees.
The primary company behind Dishman Carbogen Amcis, Dishman Carbogen Amcis Limited, reported revenue of βΉ2,988 Cr for FY 2026, up 8% year on year.
Dishman Carbogen Amcis was established in 1983 in Ahmedabad, India, by founder Janmejay R Vyas. Operations are centered on contract development and manufacturing services for active pharmaceutical ingredients within the pharmaceutical sector. Production facilities are maintained in India, supporting API synthesis and related processes for international clients. The focus remains on reliable manufacturing capabilities without additional diversification noted.
Dishman Carbogen Amcis's top competitors include Laurus Labs, Symbiotec and SeQuent.
Dishman Carbogen Amcis offers CRAMS Services, API Manufacturing, Analytical Capabilities, Finished Dosages, and Quaternary Salts.
Yes, Dishman Carbogen Amcis is publicly traded on NSE under the ticker symbol DCAL.
Dishman Carbogen Amcis operates through Dishman Carbogen Amcis Limited.
The legal entities of Dishman Carbogen Amcis currently have 8 directors, including Arpit Janmejay Vyas, Harshil Ramakant Dalal, Shrima Gaurangbhai Dave and others.
